Answers are grounded in this paper and cite their sources.
Febrile neutropenia (FN) remains a complication of myelosuppressive chemotherapy during granulocyte colony-stimulating factor (G-CSF) prophylaxis. This six-month, single-centre prospective observational study enrolled 130 adults consecutively at KIMS Hospital, Secunderabad, to describe FN and hospitalization during moderate-or high-intensity chemotherapy with prophylactic G-CSF. The study recorded FN using a temperature threshold of 38.3°C and concurrent absolute neutrophil count below 500 cells/mm³. Sixty-four patients received moderate-intensity chemotherapy and 66 received high-intensity chemotherapy. Seven patients developed FN (5.38%), and 20 were hospitalized during treatment (15.38%). The study summary identified seven hospitalized patients who met the FN criteria. FN and hospitalization represent distinct outcomes in this cohort. The 5.38% figure describes observed FN during prophylaxis. Estimating the effect of G-CSF would require a comparable group without prophylaxis. The findings provide a centre-specific estimate for this treated cohort.
No takes yet. Share an insight, caveat, or question.
Preethi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: